Tricuspid regurgitation (TR) is a frequent and complex problem, commonly combined with left-sided heart disease, such as mitral regurgitation. Significant TR is associated with increased mortality if left untreated or recurrent after therapy. Tricuspid regurgitation was historically often disregarded and remained undertreated. Surgery is currently the only Class I Guideline recommended therapy for TR, in the form of annuloplasty, leaflet repair, or valve replacement. As growing experience of transcatheter therapy in structural heart disease, many dedicated transcatheter tricuspid repair or replacement devices, which mimic well-established surgical techniques, are currently under development. Nevertheless, many aspects of TR are little understood, including the disease process, surgical or interventional risk stratification, and predictors of successful therapy. The optimal treatment timing and the choice of proper surgical or interventional technique for significant TR remain to be elucidated. In this context, we aim to highlight the current evidence, underline major controversial issues in this field and present a future roadmap for TR therapy.

Tricuspid valve • Tricuspid regurgitation • Imaging • Treatment • Outcome • Risk • Heart failure,
European Heart Journal
Department of Cardio-Thoracic Surgery

Chang, C.C., Veen, K.M., Hahn, R.T, Bogers, A.J.J.C, Latib, A, Oei, F.B.S, … Soliman, O.I.I. (2020). Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. European Heart Journal, 41(20), 1932–193+. doi:10.1093/eurheartj/ehz614